NEW YORK (GenomeWeb) – Bio-Rad Laboratories reported after the close of the market Tuesday that its second quarter revenues increased 14 percent year over year, driven by growth in both its Life Science and Clinical Diagnostics businesses.

For the three months ended June 30, Bio-Rad tallied net sales of $575.9 million compared to $504.7 million in Q2 2017, beating analysts' consensus estimate of $548.4 million. On a currency-neutral basis, Q2 sales increased 11 percent year over year, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.